Societal Value of Lecanemab in Japan Published in Neurology and Therapy
A recent study titled “Societal Value of Lecanemab in Japan” has been published in Neurology and Therapy. The study highlights the potential impact of Lecanemab, a promising investigational therapy for Alzheimer’s disease, on the Japanese society. Lecanemab, developed by Biogen and Eisai, has shown promising results in clinical trials by targeting the underlying cause of Alzheimer’s disease, the accumulation of amyloid plaques in the brain. The study explores the societal value of Lecanemab, focusing on its potential benefits in terms of delaying disease progression, improving patients’ quality of life, and reducing the burden on caregivers and the healthcare system. The research underscores the urgent need for effective treatments for Alzheimer’s disease, given the increasing prevalence and significant impact on individuals, families, and society as a whole.